Fri, October 30, 2020

Gena Wang Maintained (VRTX) at Buy with Decreased Target to $307 on, Oct 30th, 2020

Gena Wang of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $315 to $307 on, Oct 30th, 2020.

Gena has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $249 on, Monday, October 19th, 2020


These are the ratings of the 5 analyists that currently disagree with Gena


  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $287 on, Wednesday, October 28th, 2020
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $305 on, Friday, July 31st, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020